Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Monday. The brokerage issued a hold rating on the medical research company’s stock.

A number of other research analysts have also commented on the stock. HC Wainwright restated a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research note on Monday, November 11th. D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a research note on Friday, January 3rd. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Trading Up 3.8 %

NASDAQ CTSO opened at $1.08 on Monday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The firm has a market cap of $59.05 million, a PE ratio of -3.00 and a beta of 0.58. Cytosorbents has a one year low of $0.70 and a one year high of $1.59. The firm’s fifty day moving average is $0.92 and its two-hundred day moving average is $1.03.

Institutional Trading of Cytosorbents

A number of institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its holdings in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares in the last quarter. Atomi Financial Group Inc. purchased a new stake in Cytosorbents during the third quarter worth about $51,000. Finally, Sargent Investment Group LLC boosted its holdings in Cytosorbents by 4.9% during the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after buying an additional 67,181 shares in the last quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.